Gyre Therapeutics, Inc. Common Stock (GYRE) is a publicly traded Healthcare sector company. As of May 21, 2026, GYRE trades at $6.10 with a market cap of $624.86M and a P/E ratio of 100.58. GYRE moved -3.35% today. Year to date, GYRE is -23.74%; over the trailing twelve months it is -47.02%. Its 52-week range spans $6.01 to $19.00. Analyst consensus is buy with an average price target of $19.00. Rallies surfaces GYRE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Hedge funds tracked by Rallies that own GYRE include Renaissance Technologies. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Gyre Therapeutics, Inc. Common Stock.
| Metric | Value |
|---|---|
| Price | $6.10 |
| Market Cap | $624.86M |
| P/E Ratio | 100.58 |
| EPS | $0.06 |
| Dividend Yield | 0.24% |
| 52-Week High | $19.00 |
| 52-Week Low | $6.01 |
| Volume | 120 |
| Avg Volume | 0 |
| Revenue (TTM) | $116.59M |
| Net Income | $9.88M |
| Gross Margin | 95.36% |
2 analysts cover GYRE: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $19.00.